GAITHERSBURG, Md., May 18, 2023
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma"
or the "Company"), a global biopharmaceutical company dedicated to
discovering, developing, manufacturing, and delivering new
generations of vaccines and therapeutic biologics for infectious
diseases and cancer, today announced that it will participate in
The Benchmark Company Healthcare House Call Virtual 1x1 Investor
Conference on Tuesday, May 23,
2023.
Dr. David Shao, YS Biopharma
Chief Executive Officer, Ms. Brenda
Wu, YS Biopharma Chief Financial Officer, and Dr.
Zenaida Mojares, YS Biopharma Chief
Medical Officer, will attend and will be available for virtual
one-on-one and small group meetings.
For more information on the conference, please contact your
conference representative. Meeting requests may also be emailed to
YSBiopharma.IR@icrinc.com.
About YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated to
discovering, developing, manufacturing, and delivering new
generations of vaccines and therapeutic biologics for infectious
diseases and cancer. It has developed a proprietary PIKA®
immunomodulating technology platform and a new generation of
preventive and therapeutic biologics targeting Rabies, Coronavirus,
Hepatitis B, Influenza, Shingles, and other virus infections. YS
Biopharma operates in China,
the United States, Singapore, and the
Philippines, and is led by a management team that combines
rich local expertise and global experience in the
bio-pharmaceutical industry. For more information, please visit
investor.ysbiopharm.com.
Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-to-participate-in-the-virtual-benchmark-healthcare-house-call-conference-on-may-23-2023-301828425.html
SOURCE YS Biopharma Co., Ltd.